Gynecologic Oncology

Results of a phase II cooperative-group trial showed that the targeted agent cetuximab demonstrated minimal activity in patients with advanced, platinum-resistant cervical cancer

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)

Nektar Therapeutics announced that its oncology drug candidate, NKTR-102, has been granted orphan drug status

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Exposure to air pollution at certain times in a woman's life can leave her more susceptible to premenopausal breast cancer

Cervical cancer affects about 470,000 women each year and now the disease has a new tool to combat its spread

Contrary to the traditionally slow pace of research adoption, the American College of Surgeons Oncology Group's Z0011 trial has seemingly changed practice overnight

A breast cancer diagnosis is a highly distressing, life-changing experience

A team of researchers explored the use of drugs in terms of breast cancer prevention strategies

Iniparib remains an intriguing therapeutic possibility despite failing to meet its phase III primary endpoints

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

For the first time in at least 3 decades, the rate of women dying from lung cancer in the United States is declining

Useful Online Resources and Clinical Trials for Ovarian Cancer

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes

Tamoxifen, a common drug used to treat breast cancer, works by blocking the effect of estrogen on tumor cells.

Like the Deep South Network for Cancer Control, the Sowing the Seeds of Health program relies on community health advisors to spread the word about cancer prevention and early detection

New research suggested that concern about pain may deter obese women from undergoing mammography, while a busy schedule may dissuade women aged less than 60 years

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

New data suggest that immigration status may help explain why some women decide to be screened for cervical cancer and others do not

About 40% of insured women in the United States are not undergoing screening mammography at least every 2 years in keeping with guidelines from the USPSTF.

CYP2D6 phenotype status does not predict tamoxifen efficacy in patients with early-stage breast cancer, according to a retrospective analysis of data from the Breast International Group

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

It was 2 days after her very first mammogram when Lisa Vance got a call from her physician's office requesting that she come in to discuss the results. Even so, it never occurred to her to be worried.